Search Results | MSF Science Portal

Journal Article

|

Research

Derendinger B, Dippenaar A, de Vos M, Huo S, Alberts R, et al.

2023-12-01 • Lancet Microbe

BACKGROUND
Bedaquiline is a life-saving tuberculosis drug undergoing global scale-up. People at risk of weak tuberculosis drug regimens are a priority for novel drug access despite t...

Journal Article

|

Research

Goig GA, Menardo F, Salaam-Dreyer Z, Dippenaar A, Streicher EM, et al.

2023-06-06 • Lancet Microbe

BACKGROUND
Experimental data show that drug-resistance-conferring mutations are often associated with a decrease in the replicative fitness of bacteria in vitro, and that this fitnes...

Journal Article

|

Research

Apolisi I, Cox HS, Tyeku N, Daniels J, Mathee S, et al.

2023-02-21 • Open Forum Infectious Diseases

BACKGROUND
Children and adolescents with household exposure to multidrug- or rifampicin-resistant tuberculosis (MDR/RR-TB) are at high risk of developing TB disease. Tuberculosis pre...

Journal Article

|

Letter

Memani B, Furin J, Cox HS, Reuter A

2022-12-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Letter

Furin J, Reuter A, Eyde L, Cox HS

2022-11-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Letter

Tyeku N, Apolisi I, Daniels J, Beko B, Memani B, et al.

2022-10-01 • International Journal of Tuberculosis and Lung Disease

Journal Article

|

Research

Isaakidis P, Cox HS, Varghese B, Montaldo C, Da Silva E, et al.

2011-12-01 • PLOS One

India carries one quarter of the global burden of multi-drug resistant TB (MDR-TB) and has an estimated 2.5 million people living with HIV. Despite this reality, provision of treatment f...

Journal Article

|

Research

Sinanovic E, Ramma L, Vassall A, Azevedo VD, Wilkinson LS, et al.

2015-02-01 • International Journal of Tuberculosis and Lung Disease

SETTING
The cost of multidrug-resistant tuberculosis (MDR-TB) treatment is a major barrier to treatment scale-up in South Africa.

OBJECTIVE
To estimate and compare the c...

Journal Article

|

Short Report

Cox HS, Hughes J, Black JM, Nicol MP

2018-03-13 • Lancet Infectious Diseases

Treatment for drug-resistant tuberculosis is largely delivered through standardised, empirical combination regimens in low-resource, high-burden settings. However, individualised treatme...

Journal Article

|

Letter

Hughes J, Isaakidis P, Andries A, Mansoor H, Cox V, et al.

2015-12-01 • European Respiratory Journal

Journal Article

|

Letter

Cox HS, Sibilia C, Feuerriegel S, Kalon S, Polonsky JA, et al.

2008-11-27 • New England Journal of Medicine

Journal Article

|

Commentary

Cox HS, Ford NP, Keshavjee S, McDermid C, von Schoen-Angerer T, et al.

2011-04-01 • Lancet Infectious Diseases

Journal Article

|

Research

Cox HS, Hughes J, Daniels J, Azevedo VD, McDermid C, et al.

2014-04-01 • International Journal of Tuberculosis and Lung Disease

SETTING: Khayelitsha, South Africa, a peri-urban township with high burdens of tuberculosis (TB), drug-resistant tuberculosis (DR-TB), and human immunodeficiency virus (HIV) infection.

Journal Article

|

Research

Daniels J, Khogali MA, Mohr E, Cox V, Moyo S, et al.

2015-11-10 • PLOS One

SETTING
Khayelitsha, South Africa, with high burdens of rifampicin-resistant tuberculosis (RR-TB) and HIV co-infection.

OBJECTIVE
To describe time to antiretroviral trea...

Journal Article

|

Commentary

Cox HS, Furin J, Mitnick CD, Daniels C, Cox V, et al.

2015-07-01 • Bulletin of the World Health Organization

Approximately half a million people are thought to develop multidrug-resistant tuberculosis annually. Barely 20% of these people currently receive recommended treatment and only about 10...

Journal Article

|

Case Report/Series

de Vos M, Ley SD, Wiggins KB, Derendinger B, Dippenaar A, et al.

2019-05-30 • New England Journal of Medicine

Journal Article

|

Research

Cox HS, Kebede YYK, Allamuratova S, Ismailov G, Davletmuratova Z, et al.

2006-10-01 • PLOS Medicine

BACKGROUND: The DOTS (directly observed treatment short-course) strategy for tuberculosis (TB) control is recommended by the World Health Organization globally. However, there are few st...

Journal Article

|

Research

Salaam-Dreyer Z, Streicher EM, Sirgel FA, Menardo F, Borrell S, et al.

2021-08-30 • Antimicrobial Agents and Chemotherapy

Rifampicin mono-resistant TB (RMR-TB, rifampicin resistance and isoniazid susceptibility) constitutes 38% of all rifampicin-resistant TB (RR-TB) in South Africa and is increasing. We aim...

Journal Article

|

Letter

Cox HS, van Cutsem G, Cox V

2014-08-01 • Lancet

Journal Article

|

Letter

Cox HS, Ford NP, Hughes J, Goemaere E

2013-01-01 • Lancet Infectious Diseases

Science Portal

Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study

Effect of compensatory evolution in the emergence and transmission of rifampicin-resistant Mycobacterium tuberculosis in Cape Town, South Africa: a genomic epidemiology study

Tuberculosis diagnosis and preventive monotherapy among children and adolescents exposed to rifampicin-resistant tuberculosis in the household

A very sneaky bug: perspectives of front-line clinicians on whole-genome sequencing for drug-resistant TB

A test of infection should not be a “standard” for guiding TB preventive therapy in at-risk populations

Pediatric delamanid treatment for children with rifampicin-resistant TB

Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India

Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa

Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?

Linezolid in drug-resistant tuberculosis: haste makes waste

Emergence of extensive drug resistance during treatment for multidrug-resistant tuberculosis

Rational use of moxifloxacin for tuberculosis treatment

Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa

Time to ART initiation among patients treated for rifampin-resistant tuberculosis in Khayelitsha, South Africa: Impact on mortality and treatment success

The need to accelerate access to new drugs for multidrug-resistant tuberculosis

Bedaquiline microheteroresistance after cessation of tuberculosis treatment

Tuberculosis recurrence and mortality after successful treatment: impact of drug resistance

Rifampicin mono-resistant tuberculosis is not the same as multidrug-resistant tuberculosis: a descriptive study from Khayelitsha, South Africa

Better treatment of XDR tuberculosis needed in South Africa

Linezolid for multidrug-resistant tuberculosis